Feasibility and safety of single-fraction sub-ablative radiotherapy with systemic therapy in colorectal cancer patients with ≤ 10 metastases: A multicenter pilot study (NCT05375708)

K. Zwart, M. N.G.J.A. Braat, F. H. van der Baan, A. M. May, J. M.L. Roodhart, D. Al-Toma, J. M.M.B. Otten, M. Los, T. Oostergo, R. J.A. Fijneman, J. M. van Dodewaard-de Jong, C. J.A. Punt, G. Meijer, J. J.W. Lagendijk, M. Koopman, M. Intven, G. M. Bol*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Colorectal cancer patients with ≤10 unresectable metastases were treated with single-fraction sub-ablative radiotherapy in addition to standard of care systemic therapy in a single-arm, open-label, multicenter, pilot study (SIRIUS) to assess feasibility and safety. Results indicate that radiotherapy combined with systemic therapy is feasible and safe in this population.

Original languageEnglish
Article number100874
Pages (from-to)1-5
Number of pages5
JournalClinical and translational radiation oncology
Volume49
DOIs
Publication statusPublished - Nov 2024

Keywords

  • Oligometastases
  • phase I
  • SBRT
  • Single fraction
  • Systemic therapy

Fingerprint

Dive into the research topics of 'Feasibility and safety of single-fraction sub-ablative radiotherapy with systemic therapy in colorectal cancer patients with ≤ 10 metastases: A multicenter pilot study (NCT05375708)'. Together they form a unique fingerprint.

Cite this